Prelude Therapeutics Incorporated (PRLD)
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn moreKey Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
|
Dr. Krishna Vaddi D.V.M., Ph.D.
|
Founder, CEO & Director | 935.26k | -- | 1966 |
|
Mr. Bryant David Lim J.D.
|
CFO, Chief Legal Officer & Corporate Secretary | 681.05k | -- | 1971 |
|
Dr. Peggy A. Scherle Ph.D.
|
Chief Scientific Officer | 674.21k | -- | 1962 |
|
Ms. Aimee Crombie Ph.D.
|
Senior VP and Head of Strategic Planning & Operations | -- | -- | -- |
|
Dr. Madhu Pudipeddi Ph.D.
|
Senior Vice President of Technical Operations | -- | -- | -- |
|
Mr. Robert A. Doody Jr.
|
Senior Vice President of Investor Relations | -- | -- | -- |
|
Ms. Michele Porreca M.B.A.
|
Chief People Officer | -- | -- | -- |
|
Dr. Andrew P. Combs Ph.D.
|
Executive VP & Chief Chemistry Officer | 562.46k | -- | 1967 |
|
Mr. Naveen Babbar Ph.D.
|
Senior Vice President of Translation Medicine | -- | -- | -- |
|
Dr. Wan-Jen Hong M.D.
|
Senior Vice President of Clinical Development | -- | -- | 1979 |
Prelude Therapeutics Incorporated
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 79
Description
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing JAK2V617F, a driver mutation product for the treatment of myeloproliferative neoplasms, myelofibrosis (MF), polycythemia vera, and essential thrombocythemia (ET); KAT6A for the treatment of advanced breast cancer and other solid tumors; and mutated calreticulin degrader antibody conjugates to treat MF and ET. The company has collaboration with AbCellera Biologics to discover, develop, and commercialize novel degrader antibody conjugates. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.
Corporate Governance
Upcoming Events
November 11, 2026 at 12:30 PM UTC
Prelude Therapeutics Incorporated Earnings Date
